News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Parker Bioscience outlines its planned investment to meet demand as the industry shifts from traditional processes to biological – for which single-use products are critical, says exec.
Cel-Sci expects a final resolution this month, more than four years after filing an arbitration suit against its former CRO.
WuXi Biologics has announced plans to build a $60m manufacturing facility – offering continuous manufacturing options – for clinical and commercial production in the US.